Therapeutic Asset Ratings

462 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
177lu-fap-2286 Neoplasm	Novartis Pharmaceuticals	P1/2	CC (40)
[177lu]lu-sn201 Neoplasm	Spago Nanomedical AB	P1/2	CC (40)
1H-ISOINDOL-1-ONE, 7-((6-((DIMETHYLAMINO)METHYL)-5-((3S)-TETRAHYDRO-3-FURANYL)-2-PYRIDINYL)AMINO)-4-(7-FLUOROIMIDAZO(1,2-A)PYRIDIN-3-YL)-2,3-DIHYDRO- Neoplasm	Nimbus Saturn, Inc.	P1/2	CC (40)
23me-00610 Neoplasm	23andMe, Inc.	P1/2	CC (40)
23me-01473 Neoplasm	23andMe, Inc.	P1/2	CC (40)
4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo- Neoplasm	STORM Therapeutics LTD	P1/2	CC (40)
4scar-276 Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (40)
4scar-gd2 Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (40)
7mw3711 Neoplasm	Mabwell (Shanghai) Bioscience Co., Ltd.	P1/2	CC (40)
a2b530 Neoplasm	A2 Biotherapeutics Inc.	P1/2	CC (40)
Afnt-211 Neoplasm	Affini-T Therapeutics, Inc.	P1/2	CC (40)
Alg.Apv-527 Neoplasm	Aptevo Therapeutics	P1/2	CC (40)
Allocetra-Ots Neoplasm	Enlivex Therapeutics RDO Ltd.	P1/2	CC (40)
Allogeneic Tcr-Enhanced Vδ2 T Cell Neoplasm	Chinese PLA General Hospital	P1/2	CC (40)
AS01b Neoplasm	Universitair Ziekenhuis Brussel	P1/2	CC (40)
Ast-001 Neoplasm	Ascentawits Pharmaceuticals, Ltd	P1/2	CC (40)
at-1965 liposome Neoplasm	Alyssum Therapeutics	P1/2	CC (40)
Atamparib Neoplasm	Nerviano Medical Sciences (Shanghai) Ltd.	P1/2	CC (40)
AUTOLOGOUS RAPAMYCIN-RESISTANT TH1/TC1 CELLS RAPA-201 Neoplasm	Rapa Therapeutics LLC	P1/2	CC (40)
Balstilimab Neoplasm	Rottapharm Biotech	P1/2	CC (40)
Bhv-1510 Neoplasm	Biohaven Therapeutics Ltd.	P1/2	CC (40)
bi-4scar gd2/psma t cells Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (40)
bnt141 Neoplasm	BioNTech SE	P1/2	CC (40)
bnt142 Neoplasm	BioNTech SE	P1/2	CC (40)
Bpb-101 Neoplasm	Betta Pharmaceuticals Co., Ltd.	P1/2	CC (40)

Showing 126 to 150 of 462 assets

PreviousPage 6 of 19Next